Dihydrocaffeic acid improves IL-1β-induced inflammation and cartilage degradation via inhibiting NF-κB and MAPK signalling pathways

Aims Osteoarthritis (OA) is a prevalent joint disorder with inflammatory response and cartilage deterioration as its main features. Dihydrocaffeic acid (DHCA), a bioactive component extracted from natural plant (gynura bicolor), has demonstrated anti-inflammatory properties in various diseases. We aimed to explore the chondroprotective effect of DHCA on OA and its potential mechanism. Methods In vitro, interleukin-1 beta (IL-1 beta) was used to establish the mice OA chondrocytes. Cell counting kit-8 evaluated chondrocyte viability. Western blotting analyzed the expression levels of collagen II, aggrecan, SOX9, inducible nitric oxide synthase (iNOS), IL-6, matrix metalloproteinases (MMPs: MMP1, MMP3, and MMP13), and signalling molecules associated with nuclear factor-kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) pathways. Immunofluorescence analysis assessed the expression of aggrecan, collagen II, MMP13, and p-P65. In vivo, a destabilized medial meniscus (DMM) surgery was used to induce mice OA knee joints. After injection of DHCA or a vehicle into the injured joints, histological staining gauged the severity of cartilage damage. Results DHCA prevented iNOS and IL-6 from being upregulated by IL-1 beta. Moreover, the IL-1 beta-induced upregulation of MMPs could be inhibited by DHCA. Additionally, the administration of DHCA counteracted IL-1 beta-induced downregulation of aggrecan, collagen II, and SOX9. DHCA protected articular cartilage by blocking the NF-kappa B and MAPK pathways. Furthermore, DHCA mitigated the destruction of articular cartilage in vivo. Conclusion We present evidence that DHCA alleviates inflammation and cartilage degradation in OA chondrocytes via suppressing the NF-kappa B and MAPK pathways, indicating that DHCA may be a potential agent for OA treatment.

Automated summary

This study found that dihydrocaffeic acid (DHCA) can alleviate inflammation and cartilage degradation in osteoarthritis (OA) chondrocytes by suppressing the NF-kappa B and MAPK pathways. This suggests that DHCA may be a potential agent for OA treatment.